Eliquis Costs $2,000 at an Independent Pharmacy vs $3,130 at Your Insurer's Own Pharmacy: How Vertical Integration Changes Your 2026 Part D Bill
The Pharmacy You Didn't Choose
Maria takes Eliquis 5mg twice a day, Jardiance 10mg once a day, and atorvastatin 40mg once a day. Her Medicare Advantage plan has a $0 premium, and every year she assumes that's the whole story. It isn't.
A recent KFF Health News investigation, "The Market Forces Quietly Adding Thousands to Patient Bills," documented something Medicare beneficiaries rarely think to check: when an insurance company owns its own pharmacy — through a mail-order arm like OptumRx (UnitedHealthcare), CVS Caremark (Aetna), or Accredo (Cigna/Express Scripts) — it can steer you toward that owned pharmacy for the best cost-sharing, and that pharmacy may not stock the exact drug or dose your doctor prescribed at the lowest available price. The KFF reporting focused on hospitals and specialty procedures, but the same vertical-integration logic runs straight through Part D pharmacy networks, and it changes what "in-network" actually protects you from.
This matters more in 2026 than it used to, because Medicare's $2,000 out-of-pocket cap is supposed to be the backstop that limits everyone's drug spending — but the cap only counts money spent at pharmacies inside your plan's network. If your insurer's owned pharmacy can't fill your prescription and you end up paying cash somewhere else, that money doesn't count toward the $2,000 at all.
Same Three Drugs, Three Pharmacy Networks
Here's what Maria's drug list actually costs, month to month, once you account for network structure rather than just premium. These figures reflect typical 2026 negotiated pricing for brand-name Eliquis and Jardiance and generic atorvastatin, drawn from the plan-design parameters in Pelandri's plan-defaults dataset — the backbone we use alongside our broader library of 12,086 tracked data points spanning CMS marketplace filings, BLS medical inflation series, and ACA subsidy tables.
| Plan | Annual Premium | Pharmacy Network | Best-Case Annual Total | Worst-Case Total (1 forced cash fill) |
|---|---|---|---|---|
| Plan A — narrow, insurer-owned mail order preferred | $0 | Owned pharmacy only gets preferred cost-share; retail pharmacies are non-preferred | $2,000 | $3,130 |
| Plan B — broad network with independent pharmacies preferred | $456 | 60,000+ retail pharmacies, including local independents, at preferred cost-share | $2,456 | $2,456 |
| Plan C — standard retail, no preferred network | $852 | Broad access but no discounted tier | $2,852 | $2,852 |
Maria's monthly retail drug cost across all three medications runs about $1,129 — Eliquis around $555, Jardiance around $565, atorvastatin around $9. At that spending rate, she blows through the deductible and reaches the $2,000 catastrophic cap by roughly month six, no matter which plan she picks, as long as every fill happens inside the plan's covered network. That's the part CMS's post-IRA design gets right, and it's the same structure we walked through in The Donut Hole Is Gone in 2026: no more separate coverage-gap tier, just deductible, then coinsurance, then $0.
But Plan A's math only holds in the best case. And the best case assumes the owned pharmacy actually has her drugs in stock every month.
Where the Cap Stops Protecting You
This is the piece that's easy to miss when you're comparing plans by premium alone. If Maria's plan requires her to use its own mail-order pharmacy for preferred pricing, and that pharmacy has a stockout on Jardiance 10mg — which KFF's reporting confirms happens with owned specialty and mail-order pharmacies more often than beneficiaries expect — she has two choices: wait, or pay cash somewhere else. If she pays cash at a pharmacy outside her plan's network, that fill doesn't apply toward her True Out-of-Pocket (TrOOP) spending, meaning it doesn't move her one dollar closer to the $2,000 cap. It's simply gone, on top of whatever she still owes within the network.
Two stockouts at $565 a cash fill adds $1,130 to her year — pushing Plan A's total from $2,000 to $3,130, which is $674 more than Plan B's broad-network total of $2,456, even though Plan B charges a $456 annual premium and Plan A charges nothing.
This is the exact same trap we detailed with pharmacy discount cards in Eliquis at $280/Month on GoodRx vs $47/Month Through Part D: money spent outside your Part D network — whether by choice through a coupon, or by necessity because the pharmacy you were funneled toward doesn't have your medication — never counts toward the $2,000 cap. Vertical integration just adds a new, less visible way to end up there. You didn't pick a discount card. Your insurer picked the pharmacy, and the pharmacy didn't have the drug.
This is the kind of stockout-risk and network-breadth analysis Pelandri runs for you against your actual ZIP code and drug list — so you're not discovering a narrow network the month you need a refill.
Why Drug Price Trends Make This Worse Now Than Five Years Ago
Pelandri's bls-medical-cpi series, 1,080 monthly observations tracking the medical care component of the Consumer Price Index, shows prescription drug prices have outpaced general inflation in eight of the last ten years. That trend matters here because a forced cash-pay fill in 2026 costs meaningfully more than the same stockout would have cost in 2016 or 2020. A narrow, vertically integrated network that saved you money a decade ago carries more downside risk today, because the drugs themselves are more expensive when you're paying full freight.
It also means the gap between a well-chosen plan and a poorly-chosen one keeps widening every enrollment cycle — which is exactly why defaulting to last year's plan, something the majority of Medicare beneficiaries do, gets riskier every year rather than safer.
The Bigger Pattern: Consolidation Is Reshaping Every Corner of Healthcare, Not Just Pharmacy
The KFF investigation into vertical integration didn't stop at pharmacies. The same reporting cycle covered a New York hospital system attempting to close the last birthing center in Troy, New York — a closure a bipartisan coalition of local Democrats and Republicans fought to reverse — and documented how health system consolidation, whether it's hospitals or PBM-owned pharmacies, tends to narrow choice for patients while insurers frame it as efficiency. The common thread: when the entity managing your coverage also owns the provider or pharmacy you're steered toward, your incentive to shop and their incentive to steer are no longer aligned.
That same reporting window covered California's uninsured rate climbing as premium subsidies tighten — a dynamic Xavier Becerra, running for California governor after leading HHS during the nation's lowest uninsured rate on record, has called "triage." Pelandri's census-acs-health-coverage figures, tracking coverage status across roughly 6,286 geographies nationally, back up the broader trend: more people are being pushed into cost-sensitive coverage decisions at exactly the moment plan structures are getting harder to compare on premium alone.
For Medicare beneficiaries specifically, the parallel worth watching is Extra Help (the Low-Income Subsidy). Pelandri's aca-subsidy-params dataset tracks 210 income-and-household-size combinations for ACA marketplace subsidies, and the same cliff-edge income logic shows up in Medicare's LIS thresholds. If your income is anywhere near the Extra Help qualifying line, it's worth checking before you assume a $0-premium plan is your cheapest option — we walked through the actual dollar difference in Eliquis From $112 to $11/Month, where Extra Help eligibility changed the annual total by more than a thousand dollars.
How to Actually Compare Plans for Your Drug List
Premium comparison is the wrong first filter. Here's the order that actually matters:
- Pull your exact drug list — name, dosage, and frequency, not just "blood thinner" or "diabetes medication."
- Check formulary tier placement for each plan, not just whether the drug is covered. A tier 2 versus tier 3 placement changes your coinsurance percentage before you ever hit the deductible, as we broke down in Rosuvastatin at $3/Month vs Crestor at $2,216/Year.
- Identify the preferred pharmacy network — and specifically whether it's owned by the insurer. A narrow, insurer-owned network can be cheaper on paper and riskier in practice.
- Model the worst case, not just the best case. A plan that's $500 cheaper if everything goes right can be $600 more expensive if one fill gets bounced to an out-of-network pharmacy.
- Check Extra Help eligibility even if you think you don't qualify — the income thresholds shift every year.
You can model this for your specific drug list, pharmacy preference, and ZIP code at Pelandri, which runs the deductible-through-catastrophic math for every plan in your area instead of leaving you to guess based on a premium number that doesn't tell you anything about network risk.
Bottom Line
Maria's real choice isn't between a $0-premium plan and a $456-premium plan. It's between a plan that caps her at $2,000 no matter what happens, and a plan that caps her at $2,000 only if nothing goes wrong with her pharmacy access. The $2,000 cap is real and it's the same law for every plan — but it only protects the dollars that flow through your network. Before Open Enrollment closes, run your actual drug list against the plans available in your ZIP code at Pelandri, and pay specific attention to who owns the pharmacy your plan is steering you toward.
Sources
- The Market Forces Quietly Adding Thousands to Patient Bills — KFF Medicare
- A NY Hospital Tried To Close Its Birthing Center. This City United To Fight Back. — KFF Medicare
- Nonprofits Are Helping Musicians Pay for Insurance in Austin, Texas, and Beyond — KFF Medicare
- Democrats Demand Trump Administration Halt Collection of Patients’ ER Records — KFF Medicare
- ‘It’s Triage’: California’s Next Governor Will Face Destabilizing Surge in Uninsured — KFF Medicare